Panobinostat is promising for the treatment of patients with cutaneous T-cell lymphoma

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1653, 2008-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bexarotene in combination with PUVA may be a treatment option in patients with cutaneous T-cell lymphoma refractory to multiple single-agent therapies

Inpharma, Vol. 1, Iss. 1467, 2004-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Management of cutaneous T-cell lymphoma

By Duhovic Chris Child Fiona Wain E Mary

Clinical Medicine, Vol. 12, Iss. 2, 2012-04 ,pp. : 160-164

Royal College Of Physicians

Access to resources Recommend Favorite

Current and Emerging Treatment Strategies for Cutaneous T-cell Lymphoma

By Lansigan Frederick

Drugs, Vol. 70, Iss. 3, 2010-02 ,pp. : 273-286

Adis International

Access to resources Recommend Favorite

Romidepsin: In the Treatment of T-Cell Lymphoma

By Yang Lily P.H.

Drugs, Vol. 71, Iss. 11, 2011-07 ,pp. : 1469-1480

Adis International

Access to resources Recommend Favorite

The potential of pralatrexate as a treatment of peripheral T-cell lymphoma

By Dondi Alessandra Bari Alessia Pozzi Samantha Ferri Paola Sacchi Stefano

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 5, 2014-05 ,pp. : 711-718

Informa Healthcare

Access to resources Recommend Favorite